Informed Prostate Cancer Patient Support

Prostate cancer screening only for "a few thousand" at risk men Informed Prostate Cancer Support Group  |  IPCSG Special Report  ·  May 28, 2026 International Screening Update What the Decision Means and Why It Matters The UK National Screening Committee has issued its final recommendation: only men aged 45–61 with a confirmed pathogenic BRCA2 variant and a qualifying family cancer history will be offered prostate cancer screening. For the rest — including Black men who face double the population risk — the door remains closed, pending trial results still years away. Here is the full picture.    IPCSG Newsletter Staff   ·  Sources: UK NSC, Cancer Research UK, ICR, Prostate Cancer UK, Science Media Centre, NEJM, PubMed, GOV.UK Key Points for Patients The UK now has its first-ever prostate cancer screening programme — but only for men aged 45–61 with a pathogeni...

Beyond satisfaction scores: quantifying communication quality in oncology care | Prostate Cancer and Prostatic Diseases The Persuasion Problem: Why Your Urologist Won't Quantify Side Effects How financial incentives and training bias distort shared decision-making in prostate cancer care Bottom Line Up Front:   Recent research shows that physicians systematically use persuasive language and selective omission of data to steer patients toward treatments aligned with their own specialty and financial incentives. When a urologist won't give you precise numbers on side effects, that's not because the data doesn't exist—it's because precision would undermine the recommendation. This is documented, measurable, and strategy-resistant. Patients need to recognize it and counter it. The Evidence: Persuasive Language Is Real and Documented In 2024, Naser-Tavakolian and colleagues at Cedars-Sinai published an analysis of how physicians communi...

Metastatic Castration-Resistant Prostate Cancer Addition of Olaparib to Radium-223 - The ASCO Post Phase II COMRADE Trial Results Now Available Bottom Line Up Front (BLUF):   The Phase II COMRADE trial shows that adding olaparib (Lynparza), a PARP inhibitor, to radium-223 (Xofigo), a bone-targeted alpha emitter, significantly improves radiographic progression-free survival in men with bone-metastatic castration-resistant prostate cancer (mCRPC). Median radiographic progression-free survival nearly doubled (8.9 vs. 4.7 months). While toxicity increased, notably in blood cell counts, the combination was manageable and supports further development of DNA damage-targeted strategies in this patient population. Study Context & Rationale Metastatic castration-resistant prostate cancer (mCRPC) represents the most lethal form of prostate cancer. Approximately 80% of men with mCRPC develop bone metastases, a major source of morbidity and mortality. Bon...